Prospective studies demonstrated an inverse relationship between vitamin D status determined by measurement of serum or plasma 25-hydroxyvitamin D (25-OHD) and incident type 2 diabetes ([@B1]--[@B5]). However, results have not always been consistent, especially regarding associations in women ([@B2],[@B6]). Several mechanisms may explain the link between vitamin D and type 2 diabetes. These include direct and indirect effects of 1,25-OHD, the active vitamin D metabolite, on insulin secretion and action ([@B7],[@B8]). Immunomodulatory effects of vitamin D ([@B7]) could also mediate the association, as it is well established that subclinical inflammation is an important risk factor for type 2 diabetes ([@B9],[@B10]). To date, no prospective epidemiological study extensively addressed the mediating role of subclinical inflammation. Therefore, we assessed the association between 25-OHD and incident type 2 diabetes with and without adjustment for markers of inflammation. Furthermore, we examined possible interactions of 25-OHD with sex and age.

RESEARCH DESIGN AND METHODS {#s5}
===========================

Results are based on a prospective case-cohort study within the population-based Monitoring of Trends and Determinants in Cardiovascular Disease (MONICA)/Cooperative Health Research in the Region of Augsburg (KORA) cohort ([@B10]). The final study sample comprised 1,683 participants aged 35--74 years (231 male/185 female case subjects; 657 male/610 female noncase subjects). The subcohort for the case-cohort study was selected randomly, stratifying by sex and survey from a source population of 7,936 subjects without diabetes at baseline, with available blood samples and a follow-up time of ≥1 year, as previously described ([@B10]). All participants provided written informed consent.

Incident diabetes was assessed using questionnaires or interviews. Incident cases were validated by contacting the treating physician or medical chart review. The mean duration of follow-up (±SD) was 11.0 ± 4.7 years. Further details regarding study design and assessment of covariables have been described previously ([@B10],[@B11]). Serum samples collected at baseline were used to analyze 25-OHD in 2010 using an enzyme immunoassay (IDS, Frankfurt, Germany). The intra- and interassay coefficients of variation were 3.3 and 6.3%, respectively. Thirteen inflammation-related biomarkers were measured (see [Table 1](#T1){ref-type="table"}) ([@B12]). Biomarkers with skewed distributions were log transformed. Geometric means of 25-OHD and antilogs of SEs were compared with *t* tests. Cox proportional hazard models were used to assess associations between sex-specific tertiles of 25-OHD and incident type 2 diabetes. To account for the case-cohort design, correction of variance estimation was performed ([@B13]). Interactions were examined using likelihood ratio tests. *P* \< 0.05 was considered statistically significant. Evaluations were performed with the SAS software (version 9.2; SAS Institute, Cary, NC).

###### 

HRs for type 2 diabetes risk according to baseline levels of serum 25-OHD

                                                    Tertiles of 25-OHD     *P* value                                        
  ------------------------------------------------- ---------------------- ----------------------- ------------------------ ---------
  Men: median \[lower--upper\] (nmol/L)             27.7 \[5.08--36.12\]   43.9 \[36.13--54.70\]   68.0 \[54.71--153.92\]   
  Women: median \[lower--upper\] (nmol/L)           27.0 \[9.87--33.13\]   39.9 \[33.14--48.24\]   58.0 \[48.25--127.69\]   
  Number case/noncase subjects                      175/418                145/428                 96/421                   
  HR (95% CI)                                                                                                               
   Model 1[\*](#t1n1){ref-type="table-fn"}          1.0                    0.77 (0.59--1.01)       0.52 (0.38--0.70)        \<0.001
   Model 2[†](#t1n2){ref-type="table-fn"}           1.0                    0.77 (0.56--1.06)       0.63 (0.44--0.90)        0.010
   Model 3[§](#t1n3){ref-type="table-fn"}           1.0                    0.85 (0.61--1.17)       0.73 (0.50--1.05)        0.090
  Number case/noncase subjects                      99/235                 104/268                 68/293                   
  HR (95% CI)                                                                                                               
   Model 1a[\*\*](#t1n4){ref-type="table-fn"}       1.0                    0.91 (0.64--1.29)       0.55 (0.38--0.80)        0.001
   Model 2a[‡](#t1n5){ref-type="table-fn"}          1.0                    0.89 (0.58--1.38)       0.61 (0.39--0.96)        0.017
   Model 2a + WHR[‖](#t1n6){ref-type="table-fn"}    1.0                    0.92 (0.59--1.43)       0.66 (0.42--1.03)        0.036
   Model 3a + WHR[\#](#t1n7){ref-type="table-fn"}   1.0                    1.04 (0.66--1.64)       0.78 (0.48--1.27)        0.224

HRs were estimated by Cox proportional hazard models. Correction for SEs was made using the method by Barlow. Weighing was performed using survey- and sex-specific sampling weights. Tertiles of the weighted distributions in the subcohort, stratified by sex, were used. Tests for trend were conducted, assigning the median value within each tertile to the corresponding tertile. WHR, waist-to-hip ratio.

\*Model 1, adjusted for age, sex, survey, and season.

†Model 2, adjusted for factors in model 1 + BMI, lifestyle factors (i.e., smoking status \[never smoker, former smoker, current smoker\], alcohol consumption \[0, 0.1--39.9, ≥40 g/day for men; 0, 0.1--19.9, ≥20 g/day for women\], physical activity \[inactive, active\]), systolic blood pressure, total cholesterol/HDL cholesterol, and parental history of diabetes (negative, positive, unknown).

§Model 3, adjusted for factors in model 2 + C-reactive protein, interleukin-6, soluble intercellular adhesion molecule-1, and interferon-γ--inducible protein-10/CXCL10 (all coded as tertiles). Markers of inflammation, which were available in addition, include interleukin-18, macrophage-migration inhibitory factor, monocyte chemoattractant protein-1/CCL2, interleukin-8/CXCL8, adiponectin, leptin, RANTES/CCL5, transforming growth factor-β1, and soluble E-selectin.

\*\*Model 1a, adjusted for factors in model 1, based on data of surveys 2 and 3 only with available WHR measurements (*n* = 1,067).

‡Model 2a, adjusted for factors in model 2 (*n* = 1,067).

‖Model 2a + WHR, adjusted for factors in model 2 + WHR (as polynomial of degree 2) (*n* = 1,067).

\#Model 3a + WHR, adjusted for factors in model 3 + WHR (as polynomial of degree 2) (*n* = 1,067).

RESULTS {#s6}
=======

Baseline characteristics for case and noncase subjects are provided in [Supplementary Table 1](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc11-0775/-/DC1). The geometric mean serum 25-OHD concentration was 37.8 nmol/L in case and 42.0 nmol/L in noncase subjects. Significant inverse correlations with *r* less than −0.10 were observed between 25-OHD and soluble intercellular adhesion molecule-1, interleukin-6, interferon-γ--inducible protein-10/CXCL10, and C-reactive protein ([Supplementary Table 2](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc11-0775/-/DC1)). Therefore, these four markers of inflammation were considered potential mediating factors.

After adjustment for age, sex, survey, and season, high 25-OHD was strongly associated with a reduced risk for type 2 diabetes with a hazard ratio (HR) (95% CI) of 0.52 (0.38--0.70) comparing tertile extremes (*P*~trend~ \< 0.001) ([Table 1](#T1){ref-type="table"}). Further adjustment for "classic" diabetes risk factors attenuated the association but it remained statistically significant (HR 0.63 \[0.44--0.90\]; *P*~trend~ = 0.010). Additional adjustment for C-reactive protein, interleukin-6, soluble intercellular adhesion molecule-1, and interferon-γ--inducible protein-10 further attenuated the association by 16%. To examine the effect of residual confounding by body fat distribution, where available, we added waist-to-hip ratio to the "classical" risk factor model. The addition of markers of inflammation to this model attenuated the HR for the upper tertile of 25-OHD by 18% ([Table 1](#T1){ref-type="table"}). Linear regression models showed similar results, but effects remained significant for model 3 ([Supplementary Table 3](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc11-0775/-/DC1)). Interaction and stratified analyses revealed no statistically significant sex differences but stronger associations in younger (\<52 years) than in older (≥52 years) subjects. Since the third-order interaction term 25-OHD\*sex\*age-group was statistically significant (*P* = 0.010), we performed additional analyses simultaneously stratifying by age-group and sex ([Supplementary Table 4](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc11-0775/-/DC1)). In women, the inverse association was confined to those aged \<52 years (*P* for age-group\*25-OHD interaction = 0.016), whereas in men, differences between age-groups were less clear (*P* for age-group\*25-OHD interaction = 0.046).

CONCLUSIONS {#s7}
===========

This study demonstrated an independent association between serum 25-OHD and incident type 2 diabetes after adjustment for "classic" diabetes risk factors. Further adjustment for markers of inflammation attenuated the HRs for the upper tertile of 25-OHD by 16--18%, suggesting that the relationship between 25-OHD and type 2 diabetes risk may be partially mediated by subclinical inflammation. Stratified analyses demonstrated a significant association between 25-OHD and type 2 diabetes in younger (presumably mainly premenopausal) women, but not in older (most likely postmenopausal) women.

Our results are in line with three other prospective studies reporting inverse associations between 25-OHD and incident type 2 diabetes after adjustment for "classic" diabetes risk factors ([@B1],[@B2],[@B4],[@B5]). Furthermore, they support results from the Women's Health Initiative where no association between 25-OHD and type 2 diabetes was seen in postmenopausal women ([@B6]). Our study is the first prospective study on 25-OHD and type 2 diabetes risk that included a large panel of markers of subclinical inflammation. Inclusion of these markers in the regression models indicated that subclinical inflammation could be one mediating factor linking a low vitamin D status with the development of type 2 diabetes.

The current study has several strengths, including the population-based prospective design, the large number of incident case subjects, the long follow-up, and the availability of many covariables, including 13 markers of subclinical inflammation. Major limitations are the self-reported diagnoses of diabetes, single-time-point 25-OHD measurements, and missing data on fasting glucose or insulin at baseline. Also, it is conceivable that prior adjustment for more sophisticated indicators of obesity and body fat distribution could have diminished the risk reduction caused by the addition of markers of inflammation.

In conclusion, our results suggest that the relationship between vitamin D status and incident type 2 diabetes may be partially mediated by subclinical inflammation. Furthermore, they suggest a modulating role of age and possibly sex hormones that needs to be clarified in further studies.

Supplementary Material
======================

###### Supplementary Data

This article contains Supplementary Data online at <http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc11-0775/-/DC1>.
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